Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Gypensapogenin B in medicaments for treating rhinitis

A drug and rhinitis technology, applied in the application field of Gypensapogenin B in the treatment of rhinitis drugs, can solve the problems of ineffectiveness and poor efficacy of rhinitis, etc.

Inactive Publication Date: 2013-01-16
JIANGSU KANGHENG CHEM
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, antihistamine drugs such as terfenadine or antiallergic drugs such as tranilast and ketotifen are mainly used in the treatment of rhinitis. These drugs have poor or ineffective effects on chronicity and recurrent rhinitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Gypensapogenin B in medicaments for treating rhinitis
  • Application of Gypensapogenin B in medicaments for treating rhinitis
  • Application of Gypensapogenin B in medicaments for treating rhinitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1: Preparation of Gypensapogenin B tablets of the compound involved in the present invention:

[0013] Take 20 grams of compound Gypensapogenin B, add 180 grams of conventional excipients for preparing tablets, mix them, and prepare 1,000 tablets with a conventional tablet press.

Embodiment 2

[0014] Example 2: Preparation of the compound Gypensapogenin B capsule of the present invention:

[0015] Take 20 grams of the compound Gypensapogenin B, add 180 grams of conventional auxiliary materials for preparing capsules, such as 180 grams of starch, and mix them well, and encapsulate them to make 1000 tablets.

[0016] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0017] Experimental example 1. The effect of Gypensapogenin B of the present invention on allergic rhinitis caused by ovalbumin in rats

[0018] Male SD rats weighing 180-220g were intraperitoneally injected with ovalbumin 1mg and aluminum hydroxide gel 10mg, and then injected once every other day, a total of 7 times. From the 14th day, 10ul of 1mg / ml ovalbumin physiological saline solution was dripped into the nasal cavity of both sides of the rat every day, 7 times in total. Immediately after the last instillation, the number of sneezing and nasal rubbing of rats within 30 minutes was observed. The test drug was administered orally 1 hour before the last infusion of ovalbumin.

[0019] It can be seen from Table 1 that Gypensapogenin B (10, 20 mg / kg) significantly inhibited the sneezing and scratching nasal reactions in rats with allergic rhinitis caused by ovalbumin. Terfenadine 10mg / kg also showed a significant inhibitory effect.

[0020] Table 1 The effect of Gypensapogenin B o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses Gypensapogenin B for preparing medicaments for treating immunity inflammation, which is particularly suitable for preparing medicaments for treating rhinitis. By taking Terfenadine and diclofenac sodium as controls, Gypensapogenin B has definite curative effects. The application of Gypensapogenin B in preparing medicaments for treating rhinitis, involved in the invention, is disclosed for the first time. As the skeleton type is brand new, and the strong activity of Gypensapogenin B on treating rhinitis is unexpectedly strong, the possibility that any enlightenments are given by other compounds does not exist. Gypensapogenin B has prominent substantive features and has notable progress when being used for preventing and treating rhinitis.

Description

Technical field [0001] The invention relates to the application of Gypensapogenin B in the preparation of drugs for treating rhinitis. Background technique [0002] Rhinitis is a common clinical disease and frequently-occurring disease. The occurrence of rhinitis is mainly related to allergic reactions and belongs to the category of immune inflammation. At present, the treatment of rhinitis mainly uses antihistamines such as terfenadine or anti-allergic drugs such as tranilast and ketotifen. These drugs have poor or ineffective effects on the chronicity and recurrent rhinitis. Therefore, small molecule compounds with clear ingredients, controllable quality, safe and efficient, have potential value in the development of rhinitis treatment drugs. [0003] The compound Gypensapogenin B involved in the present invention was published in 2012 (Li, N. et al., 2012. Triterpenes possessing an unprecedented skeleton isolated from hydrolyzate of total saponins from Gynostemma pentaphyllum. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/58A61P11/02
Inventor 施桦冯怡吴俊华
Owner JIANGSU KANGHENG CHEM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com